CD44 and prostate cancer: We obtained the most promising results when we investigated the combination of UniPR1331 with cisplatin, due to the ability of UniPR1331 to reduce the PC3 stem marker CD44 and the well-known role of prostate cancer stem cells in chemoresistance [31].